* NextCure Inc NXTC.OQ NXTC.O is expected to show no
change in
quarterly revenue when it reports results on November 2
(estimated).
*
* Refinitiv's mean analyst estimate for NextCure Inc is for
a
loss of 63 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for NextCure
Inc is
$12.5, above its last closing price of $2.51.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.72 -0.72 -0.65 Beat 9.7
Mar. 31 2022 -0.67 -0.67 -0.74 Missed -10.7
Dec. 31 2021 -0.67 -0.67 -0.61 Beat 9.1
Sep. 30 2021 -0.66 -0.67 -0.65 Beat 2.5
Jun. -0.62 -0.61 -0.65 Missed -6.4
30 2021
Mar. 31 2021 -0.61 -0.59 -0.60 Missed -2.1
Dec. 31 2020 -0.61 -0.60 -0.54 Beat 9.7
Sep. 30 2020 -0.56 -0.57 -0.59 Missed -4.2
This summary was machine generated October 31 at 12:31 GMT. All
figures in US dollars unless otherwise stated